FierceBiotech Names Achaogen as One of the "Fierce 15" Biotech Companies of 2009

SAN FRANCISCO--(BUSINESS WIRE)--Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today that it has been selected as one of the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2009. The editors of FierceBiotech evaluated hundreds of privately-held firms based on vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position.